Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC- 7366 in Combination With Belzutifan (WELIREG™) in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

NCT06234605 is registered in ClinicalTrials.gov with HiberCell, Inc. as lead sponsor.

NCT NCT06234605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06234605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC- 7366 in Combination With Belzutifan (WELIREG™) in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
Lead sponsor
HiberCell, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 29, 2024
Completion date
November 30, 2027
Enrollment
80 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma